124 related articles for article (PubMed ID: 38453105)
21. The role of CDK6 in cancer.
Nebenfuehr S; Kollmann K; Sexl V
Int J Cancer; 2020 Dec; 147(11):2988-2995. PubMed ID: 32406095
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for CDK6 activation by a virus-encoded cyclin.
Schulze-Gahmen U; Kim SH
Nat Struct Biol; 2002 Mar; 9(3):177-81. PubMed ID: 11828325
[TBL] [Abstract][Full Text] [Related]
23. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease.
Alquézar C; Barrio E; Esteras N; de la Encarnación A; Bartolomé F; Molina JA; Martín-Requero Á
J Neurochem; 2015 Jun; 133(6):886-97. PubMed ID: 25689470
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
Bockstaele L; Bisteau X; Paternot S; Roger PP
Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459
[TBL] [Abstract][Full Text] [Related]
25. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Easton J; Wei T; Lahti JM; Kidd VJ
Cancer Res; 1998 Jun; 58(12):2624-32. PubMed ID: 9635589
[TBL] [Abstract][Full Text] [Related]
26. Targeting inhibition of microtubule affinity regulating kinase 4 by Harmaline: Strategy to combat Alzheimer's disease.
Adnan M; Anwar S; DasGupta D; Patel M; Elasbali AM; Alhassan HH; Shafie A; Siddiqui AJ; Bardakci F; Snoussi M; Hassan MI
Int J Biol Macromol; 2023 Jan; 224():188-195. PubMed ID: 36257368
[TBL] [Abstract][Full Text] [Related]
27. A cyclin D-CDK6 dimer helps to reshuffle cyclin-dependent kinase inhibitors (CKI) to overcome TGF-beta-mediated arrest and maintain CDK2 activity.
Nataraj SE; Blain SW
Cell Cycle; 2021 Apr; 20(8):808-818. PubMed ID: 33794722
[TBL] [Abstract][Full Text] [Related]
28. Low levels of cyclin D and nonfunctional Rb protein affect cdk6 association with cyclin-dependent kinase inhibitor p27(Kip1).
Kwon TK; Park JW
Biochem Biophys Res Commun; 2001 Jun; 284(1):106-11. PubMed ID: 11374878
[TBL] [Abstract][Full Text] [Related]
29. The N-terminal peptide of the Kaposi's sarcoma-associated herpesvirus (KSHV)-cyclin determines substrate specificity.
Kaldis P
J Biol Chem; 2005 Mar; 280(12):11165-74. PubMed ID: 15664993
[TBL] [Abstract][Full Text] [Related]
30. CAK-independent activation of CDK6 by a viral cyclin.
Kaldis P; Ojala PM; Tong L; Mäkelä TP; Solomon MJ
Mol Biol Cell; 2001 Dec; 12(12):3987-99. PubMed ID: 11739795
[TBL] [Abstract][Full Text] [Related]
31. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
32. Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases.
Anwar S; Khan S; Shamsi A; Anjum F; Shafie A; Islam A; Ahmad F; Hassan MI
J Cell Biochem; 2021 Oct; 122(10):1445-1459. PubMed ID: 34121218
[TBL] [Abstract][Full Text] [Related]
33. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract][Full Text] [Related]
34. Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance.
Gao X; Wu Y; Chick JM; Abbott A; Jiang B; Wang DJ; Comte-Walters S; Johnson RH; Oberholtzer N; Nishimura MI; Gygi SP; Mehta A; Guttridge DC; Ball L; Mehrotra S; Sicinski P; Yu XZ; Wang H
Cell Rep; 2023 Apr; 42(4):112314. PubMed ID: 37000627
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.
Whiteway SL; Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Foreman NK; Vibhakar R
J Neurooncol; 2013 Jan; 111(2):113-21. PubMed ID: 23138228
[TBL] [Abstract][Full Text] [Related]
36. Gamma-mangostin isolated from garcinia mangostana suppresses colon carcinogenesis and stemness by downregulating the GSK3β/β-catenin/CDK6 cancer stem pathway.
Wu AT; Yeh YC; Huang YJ; Mokgautsi N; Lawal B; Huang TH
Phytomedicine; 2022 Jan; 95():153797. PubMed ID: 34802869
[TBL] [Abstract][Full Text] [Related]
37. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications.
Yousuf M; Alam M; Shamsi A; Khan P; Hasan GM; Rizwanul Haque QM; Hassan MI
Int J Biol Macromol; 2022 Oct; 218():394-408. PubMed ID: 35878668
[TBL] [Abstract][Full Text] [Related]
38. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
[TBL] [Abstract][Full Text] [Related]
39. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
[TBL] [Abstract][Full Text] [Related]
40. ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).
Duan L; Yan Y; Wang G; Xing YL; Sun J; Wang LL
J BUON; 2020; 25(5):2279-2286. PubMed ID: 33277846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
